OBJECTIVES: Left ventricular assist device (LVAD) support is an increasingly important and successful therapeutic option for patients with end-stage heart failure. As chronic heart failure progresses, the left and right ventricles adapt by enlarging its volume and patients present for LVAD implantation with varying degrees of dilatation. By quantitatively assessing right ventricular (RV) and left ventricular (LV) volumes using 3D transoesophageal echocardiography and correlating the findings with clinical outcomes, we aim to investigate the prognostic value of LV and RV volumes for early survival after LVAD implantation.
INTRODUCTION
Long-term mechanical circulatory support, most commonly left ventricular assist device (LVAD) implantation, has rapidly matured to provide the best alternative to heart transplantation and is a viable therapeutic option with an acceptable evidence base supporting its indication (Class IIa) [1] for patients with refractory heart failure (HF). Patients classified as the American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) [2] Stage D continue to develop severe HF symptoms, despite guideline-directed medical therapy. Further clinical stratification of this patient subgroup to 7 clinical profiles was developed by the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) [3] working group.
As chronic HF progresses, systolic and diastolic function deteriorates, and the left and right ventricles adapt by enlarging and †The first two authors contributed equally to this work. increasing intraventricular volumes. This ventricular remodelling is initially beneficial for stroke volume (SV), but in the later stages of disease, detrimental effects prevail. There is evidence that progressive chamber enlargement is associated with poor prognosis [4] . Conversely, reverse remodelling achieved by optimal medical therapy improves outcomes, and such a reversal is considered to be the primary treatment goal [4] . Variability in disease progression, therapy and patient factors results in appreciable differences in the degree of right ventricular (RV) and left ventricular (LV) dilatation in patients scheduled for elective LVAD implantation.
The early survival after LVAD implantation is still critical and depends on patient selection, timing of the implantation and postoperative management. Among a plethora of factors, acute exacerbation and severity of HF and early right ventricular dysfunction or failure (RVF) are recognized as indicators for increased risk of early death after implantation. RVF occurs in 10-40% of patients who have undergone LVAD implantations [5] [6] [7] [8] .
Recently, the quality of myocardial imaging techniques has improved considerably, and magnetic resonance imaging has become the gold standard in quantification of RV and LV volumes. Furthermore, 3D echocardiography allows direct quantification of chamber volumes without assumptions on ventricular geometry, yet with less technical effort compared with magnetic resonance imaging. Previous studies have shown that quantitative measurements obtained with 3D echocardiographic data are well validated against magnetic resonance imaging-based data [9] [10] [11] . Thus, immediate quantitative measurements of ventricular volume and function are readily available from preprocedural 3D imaging using transoesophageal echocardiography for patients undergoing LVAD implantation.
However, the putative effect of the degree of preoperative RV or LV remodelling or dilatation on survival after LVAD implantation has not been systematically assessed until now.
The aim of our study was to assess preprocedural LV and RV volumes, as a product of remodelling and its therapeutic reversal, in patients scheduled for LVAD implantation and to investigate whether there was any prognostic value of these 3D echocardiographic parameters for early postoperative survival.
PATIENTS AND METHODS

Patients
This is a single-centre, case-control study using prospectively collected clinical and echocardiographic data from 65 patients scheduled for LVAD implantation at the German Heart Centre Berlin between May 2015 and March 2016. The study was approved by the institutional review board, and all patients gave informed consent.
Clinical data
The database was searched for preoperative descriptive parameters (age, gender and body mass index), parameters specific for end-organ dysfunction (creatinine, bilirubin and pro-b-type natriuretic peptide) and for postimplantation haemodynamic data within the first 48 postoperative hours (central venous pressure, cardiac output, inotropic support and mixed venous saturation).
Procedure
Sixty-five patients with Stage D HF were listed for LVAD implantation. The same heart team performed the procedure and perioperative care according to the institutional standard operating procedures. Particular attention was paid to early recognition and therapy of RVF. Patients who were at increased risk for the development of RVF, as identified by the preprocedural echocardiographic right to left end-diastolic ventricular size ratio [5] , were primarily treated with inhaled nitric oxide. Our institutional criteria for post-procedural diagnosis of RVF, previously published in the iNOT study [12] , were as follows: cardiac output <2.0 l/min/m 2 , mixed venous saturation <55%, mean arterial pressure <50 mmHg, high pharmacological RV support and echocardiographically determined RV dilatation with simultaneously collapsed left atrium and left ventricle. If a patient met one or more of these criteria, the intraoperative decision was made for temporary RVAD implantation after weaning from cardiopulmonary bypass.
Echocardiography
According to the updated recommendation by the American Society of Echocardiography and the European Association of Cardiovascular Imaging for chamber quantification [13] , standard transoesophageal views for assessment of right and left ventricles are acquired and digitally stored using Vivid E9 (GE) and Epiq 7 (Philips) Ultrasound machines. Preprocedural echocardiography was performed about 45 min after the induction of anaesthesia in steady state prior to the onset of surgery. The 3D workflow starts with an optimized 2D 4-chamber view with the left ventricle aligning in the middle of the sector and is followed by full 3D imaging. Appropriate depth and lateral and elevational widths are adjusted to render the complete left ventricle visible. To achieve the necessary frame rate of more than 30 frames per second, multibeat acquisition of 4-6 beats is used. To avoid stitching artefacts, ventilation was paused after preoxygenation with 100% oxygen. The apnoeic pause is limited to <60 s. Similarly, the 3D workflow for the right ventricle starts with a 4-chamber view and turning of the probe to the right to optimize the 2D image of the right ventricle (Fig. 1A) . After commencing 3D acquisition, full volume and pulmonary valve visibility are checked and multibeat acquisition is performed as described earlier.
Analysis of the preprocedural transoesophageal echocardiography data was performed by an experienced echocardiographer who was blinded to the outcome parameters. For comprehensive LV and RV volumetric quantitative evaluation (Fig. 1B) , standard TOMTEC tools were used (TOMTEC Imaging Systems, Unterschleissheim, Germany). This software is based on surface quantification of chamber volumes in each frame of the stored data, and measurement is independent of geometric assumptions for ventricular geometry. Linear dimensions, areas, volumes and functional parameters for the left and right ventricles were evaluated.
Clinical outcome
The major focus of this study is early postoperative outcome with the primary end-point of 60-day mortality and a secondary end-point of long-term survival.
Statistical analysis
Patients were stratified according to 60-day mortality and divided into 60-day survivors and 60-day non-survivors. The Mann-Whitney U-test and the Fisher's exact test were used to compare the patient groups. Optimal cut-offs for putative prognostic parameters of 60-day mortality were determined by receiver operating characteristics curves and Youden's J-statistic. Independent predictors of 60-day mortality were identified by multivariable logistic regression analysis. Predictors of long-term survival were identified by the multivariable Cox regression proportional hazards model. In both cases, variables presenting with P < 0.1 in univariable analyses were included in the initial multivariable models, which were then optimized according to the Akaike information criterion by backwards stepwise elimination of variables. Biventricular chamber end-diastolic volume index was removed from the models because of co-linearity with indexed LV enddiastolic volume (LVEDVi). The Kaplan-Meier survival curves are presented to illustrate the difference in mortality between patients with severely versus moderately dilated RVs.
RESULTS
A total of 65 patients scheduled for LVAD implantation met the inclusion criteria. Four primary pathologies caused end-stage HF in this patient cohort: 39 patients had dilated cardiomyopathy (CMP), 24 patients had an ischaemic CMP, 1 patient was diagnosed with hypertrophic obstructive CMP and 1 patient developed CMP after therapy for oncological disease. All patients were implanted with the latest generation of centrifugal LVAD continuous-flow technology. In 46 patients, HeartWare HVAD (HeartWare, Framingham, MA, USA) devices were used, and 19 patients received a HeartMate 3 (St. Jude Medical, St Paul, MN, USA). Sixty-three implantations were performed conventionally using a cardiopulmonary bypass, whereas in the remaining 2 patients, a novel minimal invasive technique using a bilateral approach without cardiopulmonary bypass was applied [14] . Additional elective surgical procedures were necessary in 22 patients: persistent foramen ovale/atrial septal defect closure (10 patients), tricuspid valve repair (5 patients), aortic valve replacement (3 patients), LV thrombectomy (4 patients) and left atrial appendage occlusion (1 patient).
Sixteen patients died within 60 days after implantation. Thus, we divided our cohort group into 60-day survivors (49 patients, 75%) and 60-day non-survivors (16 patients, 25%). Post-procedural RVF occurred in 18 patients [survivors 12 (24.5%), non-survivors 6 (37.5%); P = 0.191]. Temporary right ventricular assist device (RVAD; CentriMag, Levitronix LLC, Waltham, MA, USA) implantation was performed in 10 patients [survivors 5 (10%), non-survivors 5 (31%)]. Five RVADs were implanted on the day of surgery, 3 on the following day and 2 on Day 4. The only major difference in preoperative data was noted for LVEF, which was significantly lower in patients requiring RVAD (10.4 ± 1.3 vs 15.1 ± 0.3, P = 0.03). In 3 of the 5 survivors, RVAD was explanted after 14, 20 and 23 days, respectively, and these patients are still alive. Two patients were converted to RVAD HeartWare after 29 und 75 days: 1 patient died 376 days later, and the other is still alive. The 5 non-survivors died on RVAD after 2, 3, 5, 15, and 19 days, respectively. In the group diagnosed with dilated CMP, 6 (15%) patients died, and among those with ischaemic cardiomyopathy, mortality was 42% (10 patients). Causes of death were multiorgan failure (9 patients), RVF (6 patients) and generalized cerebral oedema (1 patient). Table 1 summarizes the clinical and demographic characteristics of both groups. The only significant difference between the groups was higher average age of 60-day non-survivors (62 ± 12 vs 55 ± 12, P = 0.02). There were no significant differences in gender distribution, body mass index, INTERMACS profiles (ranging from 2 to 4) and the indicators for end-organ dysfunction. Table 2 describes the postoperative course. The following parameters were used to reflect the postoperative haemodynamic status in the first 48 h after LVAD implantation: minimal mean arterial pressure, minimal cardiac index, lowest mixed venous saturation, maximal central venous pressure and maximal inotropic support [15] . Patients in the 60-day non-survivors group required significantly higher maximal inotropic support (68 ± 51 vs 36 ± 20; P = 0.02). Table 3 shows quantitative parameters from preprocedurally acquired echocardiographic recordings. There was no difference in linear dimensions of RV, but LV end-diastolic diameter was lower in the non-survivors group (6.72 ± 0.83 vs 7.69 ± 1.25; P = 0.007) and the right to left end-diastolic ratio (R/L ratio) was significantly higher in the 60-day non-survivors group (0.70 ± 0.09 vs 0.62 ± 0.11; P = 0.01). There were no significant differences in functional parameters acquired in 2D (tricuspid annulus plane systolic excursion and fractional area change) and by 3D echocardiography (SV index, LV global longitudinal strain and RV free wall longitudinal strain).
However, LV, RV and overall heart end-diastolic volumes were found to be significantly different between the 2 groups. Values for chamber volumes are given as body surface-adjusted indices and are higher in the 60-day survivors group (LV volume 154 ± 51 ml/m 2 vs 110 ± 40 ml/m 2 , P = 0.004; RV volume 96 ± 27 ml/m 2 vs 80 ± 23 ml/m 2 , P = 0.05; heart 250 ± 64 ml/m 2 vs 190 ± 57 ml/m 2 , P = 0.003). Supplementary Material, Fig. S1 shows concordance between linear dimension (RV end-diastolic diameter) and volume of RV (RV end-diastolic volume). The inflection points for maximal differentiation of echocardiographic parameters for risk identification of 60-day mortality are listed in Table 4 . All were determined by construction of receiver operating characteristics curves and selected at the maximum sum of sensitivity and specificity. Results of univariable prescreening for ratios (linear and volume values) and enddiastolic values for RV, LV and heart volumes show a potential to predict 60-day mortality.
The Kaplan-Meier survival curves (Fig. 2) for patients with indexed right ventricular end-diastolic volume (RVEDVi) >82 ml/ m 2 vs RVEDVi < _82 ml/m 2 show better 1-year survival (P = 0.005), with a pronounced difference occurring within the first 60 days after LVAD implantation.
The variables initially included in the logistic regression analysis for 60-day mortality were age, ischaemic versus dilatative CMP, R/L ratio >0.67, R/L end-diastolic volume >0.80, RVEDVi < _82 ml/m 2 , LVEDVi < _144 ml/m 2 and creatinine concentration. Only R/L ratio and RVEDVi < _82 ml/m 2 were independently associated with 60-day mortality (Table 5 ). The variables initially included in the Cox proportional hazards model for long-term survival were age, ischaemic versus dilatative CMP, R/L ratio >0.67, R/L end-diastolic volume >0.80, RVEDVi < _82 ml/m 2 , LVEDVi < _144 ml/m 2 and creatinine and bilirubin concentrations. In addition to R/L ratio and RVEDVi, age was associated with long-term survival (Table 6 ).
DISCUSSION
The first major finding of our study in patients scheduled for LVAD implantation is that the right ventricle in all patients was severely dilated (92 ± 27 ml/m 2 ) compared with normal values (61 ± 13 ml/m 2 ) [13] and RV ejection fraction was severely reduced at 23 ± 9%.
The second important, and somewhat surprising, finding is that more severe RV (indexed end-diastolic volume >82 ml/m 2 ) dilatation was seemingly advantageous for early outcome following LVAD implantation.
Ventricular remodelling, measured as chamber enlargement, is a primary adaptive process in chronic global or regional myocardial impairment. Although this compensatory mechanism is beneficial in HF patients to maintain SV, the long-term effect is disadvantageous [16] . Interventions limiting ventricular dilatation (remodelling) and neurohumoral activation are associated with improved survival [17] . Patients in Stage D, such as in our study, present with substantial LV and RV dilatation as a common final (41) 2 of 28 (7) 0.003 RVEDVi: 82 ml/m 2 10 of 24 (42) 6 of 42 (14) 0.018 Heart EDVi: 256 ml/m pathway for different pathologies, different therapies and variability in disease progression. In the setting of LVAD implantation, the main therapeutic aim is to increase cardiac output, determined by LVAD flow, to normal values. This haemodynamic change leads to a major increase of venous return to the right ventricle. This immediate increase in RV preload may exceed the mechanically unsupported ability of the right ventricle to increase its SV accordingly, resulting in RV failure after LVAD implantation. We expected that right ventricles with less remodelling (i.e. less dilatation) would be able to better deal with this increase of venous return. Unfortunately, our data showed an unexpected protective effect of more advanced RV dilatation. We can only speculate as to why seemingly more severely dilated right ventricles with greater RVEDVi confer a benefit on short-term survival. In addition to increasing RV preload, LVAD implantation also induces a marked decrease of RV afterload due to the resolved LV congestion [18] . It seems possible that right ventricles with greater dilation profit more from the decreased afterload, while the relative increase in preload is smaller due to the greater baseline volume prior to LVAD implantation.
Thus, more severely remodelled/dilated RVs might be able to better deal with the increase of venous return due to LVAD implantation.
Kiernan et al. [19] used 3D echocardiography in 26 patients for assessment of RV volumes and suggested RVEDVi >62 ml/m 2 as a predictor of RVF after LVAD implantation, which seems to contradict our findings. However, that study essentially compared patients with normal RV size to patients with moderately increased RV, while in our cohort patients with severely dilated RV were compared to patients with moderately increased RV volumes.
The 60-day mortality of 25% is higher than that reported in the INTERMACS registry. This may be explained by the low preprocedural INTERMACS profiles of our patient cohort, with 51% of patients presenting with profile 2 and 35% with profile 3. Nearly all deaths (15, 94%) were due to RVF or multiorgan failure. Despite the use of standard operating procedures for early management of RVF, early mortality also depends on the timing of surgery, the clinical preoperative patient status and general postoperative management.
In our previous study, we presented R/L ratio as a valuable predictor of RVF after LVAD implantation [5] . Our results were later confirmed by Vivo et al. [20] with nearly the same cut-off value for R/L ratio (0.75 vs 0.72). In this study, R/L ratio is also predictive for 60-day mortality.
Limitations
Our study shares all the typical limitations of retrospective analyses, which include severe weaknesses of a post hoc design and analysis, the inability to harvest data on all important variables/ risk factors and to standardize the indication for the primary intervention [21] . Yet the variables that were included in our final multivariate models have been shown to have an impact on 60-day survival.
We analysed a mixed patient population including both ischaemic and dilated aetiology of CMP. Because ischaemic CMP was associated with higher mortality while dilated CMP may result in greater RV or LV volumes, this could severely bias our results towards greater mortality among patients with only moderately dilated right or left ventricle. Therefore, we analysed ventricular dimensions according to the aetiology of CMP and did not detect any difference: RVEDVi (92.6 ± 28.3 vs 91.5 ± 26.7 ml/m 2 ); LVEDVi (143 ml/m 2 in both groups) and LV end-diastolic diameter (7.5 vs 7.4 cm in patients with dilated versus ischaemic CMP). Nevertheless, we included the aetiology of CMP in the initial multivariable models; however, it was not confirmed as an independent predictor of mortality.
Another limitation is the relatively small number of patients. However, patients were treated by the same heart team within a relatively short observation time for this type of therapy and all received technically similar centrifugal LVAD devices from only 2 manufacturers, which may be expected to result in a rather homogeneous patient cohort. Nevertheless, at best, these data can be used to inform a prospective controlled trial to confirm the relevance of cardiac chamber volume parameters for risk stratification of patients undergoing LVAD implantation and to develop effective therapeutic strategies accordingly.
CONCLUSION
3D echocardiography is established as a valuable tool for volume measurements, independent of assumptions on chamber geometry and readily available in preprocedural examinations prior to LVAD implantation. Moderately increased RVEDVi identified patients with higher early and late postoperative risks, while severe RV dilatation seemed to be protective. In future, postoperative management of patients with moderately dilated RV should be focussed on adjusting individually appropriate LVAD flow and providing frequent follow-ups.
